Jason Hoitt - 10 Feb 2023 Form 4 Insider Report for Provention Bio, Inc.

Role: Chief Commercial Officer
Signature: /s/ Thierry Chauche, as attorney-in-fact
Issuer symbol: N/A
Transactions as of: 10 Feb 2023
Net transactions value: -$45,005
Form type: 4
Filing time: 14 Feb 2023, 18:16:24 UTC
Previous filing: 11 Jan 2023
Next filing: 27 Apr 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PRVB	Common Stock	Sale	$45,005	-4,500	-100%	$10.00	0	10 Feb 2023	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 2, 2022.
F2	The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.00 to $10.02 per share, inclusive. The reporting person undertakes to provide to Provention Bio, Inc., any security holder of Provention Bio, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

Content

The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 2, 2022.

The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.00 to $10.02 per share, inclusive. The reporting person undertakes to provide to Provention Bio, Inc., any security holder of Provention Bio, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.